The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
News Archive
News Archive Navigation
icon
Showing 42 results
October 2021
-
Media ReleaseNovartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining…
-
Media ReleaseNovartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is…
-
Media ReleaseNew campaign highlights urgent need for action to address the growing crisis of preventable vision loss and blindnessThis World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their…
-
Media ReleaseNovartis and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)Dorval, Quebec, October 13, 2021 — Novartis Pharmaceuticals Canada Inc. today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent…
-
Media ReleaseNovartis Pharmaceuticals Canada Inc. announces digital innovation partnership in multiple sclerosis with Innodem NeurosciencesClinical trial will study new technology that tracks eye movement to assist diagnosis and monitor disease progression Dorval, Quebec, October 5, 2021 — Novartis Pharmaceuticals Canada Inc. (…
April 2021
-
Media ReleaseIlaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still’s diseaseThe approval of Ilaris (canakinumab) in the treatment of adult-onset Still’s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening…
-
Media ReleaseAlberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)iExpansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell…
-
Media ReleaseNovartis in Canada named a Top 50 Best Workplace™ in the countryOpen feedback by Novartis associates contributed to coveted Canadian employer recognition Novartis ranked among the companies with the highest levels of trust and most inclusive cultures in the…